Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) EPS (Basic): 2016-2024

Historic EPS (Basic) for Denali Therapeutics (DNLI) over the last 9 years, with Dec 2024 value amounting to -$2.57.

  • Denali Therapeutics' EPS (Basic) rose 21.84% to -$0.68 in Q4 2024 from the same period last year, while for Dec 2024 it was -$2.58, marking a year-over-year decrease of 145.71%. This contributed to the annual value of -$2.57 for FY2024, which is 142.45% down from last year.
  • Denali Therapeutics' EPS (Basic) amounted to -$2.57 in FY2024, which was down 142.45% from -$1.06 recorded in FY2023.
  • In the past 5 years, Denali Therapeutics' EPS (Basic) registered a high of $0.65 during FY2020, and its lowest value of -$2.60 during FY2022.
  • Moreover, its 3-year median value for EPS (Basic) was -$2.57 (2024), whereas its average is -$2.08.
  • Its EPS (Basic) has fluctuated over the past 5 years, first soared by 131.40% in 2020, then plummeted by 467.69% in 2021.
  • Yearly analysis of 5 years shows Denali Therapeutics' EPS (Basic) stood at $0.65 in 2020, then crashed by 467.69% to -$2.39 in 2021, then fell by 8.79% to -$2.60 in 2022, then spiked by 59.23% to -$1.06 in 2023, then tumbled by 142.45% to -$2.57 in 2024.